KYORIN Pharmaceutical 富山パチスロ., Ltd.

富山パチスロ
Contact Us
Sitemap

日本語
English

Site Search

About 富山パチスロ
About 富山パチスロ
KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. 富山パチスロ., Ltd and has changed its trade name to “KYORIN Pharmaceutical. 富山パチスロ., Ltd.” on April 2023.
Investor Relations
Investor Relations
This section provides information on the Long-term vision, medium-term business plan, financial and performance results, IR library and stock.
Sustainability
Sustainability
Following our corperate philosophy, 富山パチスロ Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.
R&D
R&D
A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

Site Search

日本語
English

KYORIN Pharmaceutical 富山パチスロ., Ltd.

About 富山パチスロ

Investor Relations

Sustainability

R&D

富山パチスロ Release
Contact Us
Site Map

富山パチスロ

Top
富山パチスロ
富山パチスロ

富山パチスロ

March 6, 2023

Please see the PDF file below for details.

富山パチスロ [ 105.9 KB ]

Previous Article
Next Article

Archive

2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006

Go to page top Top

KYORIN Pharmaceutical 富山パチスロ., Ltd.Top

About 富山パチスロ

Investor Relations

Sustainability

R&D

Handling of personal information
Terms and conditions
Social Media Policy
Recommended environment / Web accessibility

©2023 KYORIN Pharmaceutical 富山パチスロ., Ltd. All Rights Reserved.